Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers - Cancer Currents Blog

National Cancer Institute sent this bulletin at 04/24/2024 10:37 AM EDT

Having trouble viewing this email? View it as a Web page.

Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers
04/24/2024
	FDA approved mirvetuximab soravtansine-gynx (Elahere) to treat people with advanced, platinum-resistant ovarian cancer whose tumors overproduce a protein called FR-α. The full approval was based on the results of a large, randomized trial called MIRASOL, which showed Elahere improved survival for these people.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.